CIRM Funded Clinical Trials

A Phase 1b/2 Trial of the Anti-CD47 Antibody Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer


Mark Chao
Disease Area: 
Investigator:
Institution:
CIRM Grant:
Award Value:
$10,234,048
Trial Sponsor:
Trial Stage: 
Phase 1/2
Trial Status: 
Recruiting
Targeted Enrollment:
112
ClinicalTrials.gov ID:
Details: 

CD47 is overexpressed on cancer and cancer stem cells and prevents their elimination by phagocytic macrophages by delivering a potent "don't eat me" signal. Hu5F9-G4 is a humanized monoclonal antibody (mAb) that binds to CD47 and blocks its interaction with its receptor, thereby enabling phagocytosis of cancer cells. Anti-CD47 is highly synergistic in combination with other anti-cancer therapies including tumor-targeting mAbs such as cetuximab.

Design: 

Single arm, non-randomised study.

Goal: 

Safety. Dosing. Efficacy - objective response rate (ORR)

Status: 

Ongoing.